News
COVID-19: U.S. cardiology groups reaffirm continued use of RAAS-active drugs
March 18, 2020
Experts give ACE inhibitors and ARBs, cornerstones of cardiology therapy, a thumbs up despite a hypothetical adverse COVID-19 effect.
News
FDA advises stopping SGLT2 inhibitor treatment prior to surgery
March 18, 2020
The changes affect canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, and were made because surgery may put patients taking SGLT2 inhibitors at a higher risk of ketoacidosis.
![1]()
News
PARAGON-HF: Optimal systolic pressure in HFpEF is 120-129 mm Hg
March 18, 2020
In largest-ever HFpEF trial, SBP of 120-129 mm Hg was associated with lowest cardiovascular risk.
![1]()
News
ICH survival lags in the community setting
March 17, 2020
LOS ANGELES – An observed 6-month mortality of 64% in a Dutch study contrasts with better survival in interventional trials.
![1]()
News
Trump to governors: Don’t wait for feds on medical supplies
March 16, 2020
President Trump outlined new guidance for Americans to avoid gatherings of more than 10 people.
News
ESC says continue hypertension meds despite COVID-19 concern
March 16, 2020
European Society of Cardiology cites lack of data for theoretical link between ACE inhibitors and ARBs with COVID-19 infection risk.
News
Risk factors for death from COVID-19 identified in Wuhan patients
March 11, 2020
The odds of dying in the hospital increased with age, higher SOFA score, and D-dimer level exceeding 1 mcg/L.
![1]()
News
AUGUSTUS: Apixaban surpassed warfarin despite prior stroke or thromboembolism
March 7, 2020
LOS ANGELES – Secondary AUGUSTUS analysis showed ACS/PCI patients with AFib plus prior stroke, TIA, or thromboembolism did better on apixaban.
![1]()
News
AFib patients do best on a DOAC started 7-10 days post stroke
March 4, 2020
LOS ANGELES – Observational data hints at the best time to start oral anticoagulation in AFib patients after a cardioembolic stroke.
News
MACE benefits with dapagliflozin improve with disease duration
March 4, 2020
Findings suggest treatment with the SGLT-2 inhibitor should be initiated early in some high-risk patients.
